Read articles from North America

July 31, 2026 by healthday.com

Cancer risk should not be discussed through headlines alone. New modelling on vaping and future cancer burden raises important questions about long-term outcomes, but it also depends on the comparison being made: continued smoking, complete cessation, dual use or full switching. The crucial distinction remains combustion, which drives the overwhelming burden of tobacco-related cancer. Public health communication should examine emerging risks without obscuring the far greater danger of cigarettes.

July 31, 2026 by medicalxpress.com

A lower-nicotine cigarette may change the product, but it does not remove the need for a serious quit conversation. Smokers still need clear support, realistic options and honest information about why burning tobacco causes so much harm. Any move to reduce nicotine in cigarettes should be paired with access to effective cessation tools, including lower-risk nicotine alternatives where appropriate. Otherwise, policy may weaken dependence on paper while leaving people without a workable route away from smoking.

July 30, 2026 by daily-pouch.com

The skin-healing question sits in a wider clinical grey area: what should patients be told when the evidence is still developing? Vaping should not be presented as harmless, but neither should it be discussed as though it carries the same exposure profile as smoking. For wound recovery, surgery and tissue repair, the useful message is precision: identify possible risks, explain uncertainty, and keep combustion in a separate risk category. Clinical advice is strongest when it helps people understand degrees of harm, not just avoid nuance.

July 28, 2026 by regulatorwatch.com

Nicotine pouches sit at the intersection of science and politics — and the two are not always moving in the same direction. Evidence can help distinguish smoke-free products from cigarettes, but political pressure often pushes them into the same moral category. That contrast matters because regulation shaped by fear may ignore differences in exposure, risk and use. The battle over pouches is ultimately a test of whether policy can follow evidence when the politics becomes uncomfortable.

July 28, 2026 by regulatorwatch.com

Nicotine pouches sit at the intersection of science and politics — and the two are not always moving in the same direction. Evidence can help distinguish smoke-free products from cigarettes, but political pressure often pushes them into the same moral category. That contrast matters because regulation shaped by fear may ignore differences in exposure, risk and use. The battle over pouches is ultimately a test of whether policy can follow evidence when the politics becomes uncomfortable.

July 27, 2026 by clearingtheair.eu

A 74% fall in youth vaping changes the way the problem should be described. If use is declining sharply, the “epidemic” label may no longer reflect the evidence — and policy should adapt accordingly. Youth access still requires enforcement, but exaggerating the scale of the issue can distort public perception and justify restrictions that also harm adult smokers. Good public health depends on accurate labels, not outdated alarm.

July 27, 2026 by yahoo.com

Heat is no longer an abstract climate issue when people are trying to sleep, work or stay safe in homes built for a cooler past. The air-conditioning debate shows how quickly adaptation becomes political: some see cooling as wasteful, others as basic protection against extreme heat. A serious response should not shame people for needing relief, but make cooling cleaner, more efficient and more accessible. Climate policy has to help people live with the risks already here, not only argue about the emissions still to come.

July 24, 2026 by filtermag.org

When a company built around flavoured vaping products is pushed out by regulation, the impact does not stop at the business itself. It also affects the adults who relied on those products to make switching from cigarettes work. The FDA’s approach to flavours has treated adult preference as a regulatory problem rather than part of why harm reduction succeeds. A market without appealing legal alternatives is not safer if smokers are left with cigarettes.

July 22, 2026 by disobedientmargins.com

Persistent smoking should be understood not only as an individual behaviour, but also as an indicator of policy limitations. When existing interventions fail to reach certain groups of smokers, harm reduction becomes an important complement to prevention and cessation. Safer nicotine products may reduce exposure to the toxicants associated with combustion, particularly among adults who do not quit through conventional routes. The warning signal is therefore not the existence of alternative nicotine use, but the failure to integrate risk-proportionate strategies into tobacco control.

July 20, 2026 by washingtonexaminer.com

Cigarettes remain on shelves, while safer alternatives are fought in court. That contradiction sits at the heart of too much nicotine policy: the product causing the greatest harm stays legally protected, while tools that may help adults stop smoking face endless resistance. Regulation should not make the less harmful option harder to access than the deadly one. Public health loses its logic when it treats harm reduction as the problem and cigarettes as the default.